Kiromic Biopharma Inc - ESG Rating & Company Profile powered by AI
The ESG rating includes seventeen UN Sustainable Development Goals including: 'Zero Hunger', 'Responsible Production & Consumption' and 'Life on Land'. Scroll down to the end of this page for potential risks for Kiromic Biopharma Inc based on sector, location and size. This Sustainability rating for Kiromic Biopharma Inc indicates its transparency towards the United Nations SDGs.
Kiromic Biopharma Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.1; made up of an environmental score of 8.0, social score of 3.2 and governance score of 4.0.
5.1
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 958 | Provectus Biopharmaceuticals Inc | 5.2 | High |
| 958 | Vectura Group Services Ltd | 5.2 | High |
| 999 | Kiromic Biopharma Inc | 5.1 | High |
| 999 | Aequus Pharmaceuticals Inc | 5.1 | High |
| 999 | BioRestorative Therapies Inc | 5.1 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Kiromic Biopharma Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Kiromic Biopharma Inc report the average age of the workforce?
Sign up for free to unlockDoes Kiromic Biopharma Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Kiromic Biopharma Inc offer flexible work?
Sign up for free to unlockDoes Kiromic Biopharma Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Kiromic Biopharma Inc conduct supply chain audits?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Kiromic Biopharma Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose water use targets?
Sign up for free to unlockDoes Kiromic Biopharma Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Kiromic Biopharma Inc have a product recall in the last two years?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Kiromic Biopharma Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Kiromic Biopharma Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose parental leave metrics?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Kiromic Biopharma Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Kiromic Biopharma Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Kiromic Biopharma Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose its waste policy?
Sign up for free to unlockDoes Kiromic Biopharma Inc report according to TCFD requirements?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose energy use targets?
Sign up for free to unlockDoes Kiromic Biopharma Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Kiromic Biopharma Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Kiromic Biopharma Inc
These potential risks are based on the size, segment and geographies of the company.
Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.